Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Artelo Biosciences, Inc. - Common Stock (NQ:ARTL)

6.520 -0.680 (-9.44%)
Streaming Delayed Price Updated: 12:43 PM EDT, Jun 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Artelo Biosciences, Inc. - Common Stock

< Previous 1 2 3 Next >
This UnitedHealth Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Via Benzinga
EXCLUSIVE: Artelo Biosciences' New Peer-Reviewed Research Shows Effectiveness Of Psoriasis Candidate In Animal Models
Artelo Biosciences advances ART26.12 for psoriasis and CIPN, while ART27.13 shows early promise in cancer-related anorexia studies. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Recap: Artelo Biosciences Q4 Earnings
Via Benzinga
Recap: Artelo Biosciences Q3 Earnings
Via Benzinga
Artelo Q2 Net Loss Declines 33% YoY, Here Is What You Need To Know
Artelo Biosciences, Inc. 
Via Benzinga
EXCLUSIVE: Artelo Biosciences Concludes First Cohort Of Healthy Volunteers Of FABP Inhibitor Program
Artelo Biosciences advances its pipeline with ART26.12 for neuropathic pain and ART27.13 for cancer-related anorexia, targeting 2025 milestones. 
Via Benzinga
ARTL Stock Earnings: Artelo Biosciences Beats EPS for Q2 2024
ARTL stock results show that Artelo Biosciences beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
ARTL Stock Earnings: Artelo Biosciences Beats EPS for Q1 2024
ARTL stock results show that Artelo Biosciences beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
ARTL Stock Earnings: Artelo Biosciences Misses EPS for Q4 2023
ARTL stock results show that Artelo Biosciences missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Artelo Biosciences: Q1 Earnings Insights
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Why WestRock Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Why Toro Are Trading Lower By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers American Rebel Holdings, Inc. (NASDAQ: AREB) shares jumped 100% to $1.7909 after the company's subsidiary Champion Safe has been bombarded with calls from safe dealers and customers looking for... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're diving into the biggest pre-market stock movers as we check out all of the hottest news happening on Thursday morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Cannabis Stock Gainers And Losers From August 24, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Marijuana Stock Movers For August 15, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Five Studies Point To Effectiveness Of Artelo Biosciences' CBD Drug Candidate For Cancer Pain – FDA IND Application The Next Step
Greg Gorgas, President & CEO of Artelo Biosciences (NASDAQ: ARTL), was recently a guest on Benzinga’s All-Access. 
Via Benzinga
Cannabis Stock Movers For July 24, 2023
Via Benzinga
Artelo Unvails New Data On ART26.12 Demonstrating Positive Effects In Multiple Models Of Neuropathic Pain
Professor Saoirse O’Sullivan, vice president of translational sciences at Artelo Biosciences, Inc. 
Via Benzinga
Artelo Biosciences Presents Groundbreaking Research At Annual CBD Symposium In Canada
Artelo Biosciences, Inc. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Artelo Enters Next Phase Of Evaluation Of Its Cannabinoid Receptor Targeting Drug For The Treatment Of Cancer-Related Anorexia And Weight Loss
Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.